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IFN-free therapyDue to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide
and probable long-term presence in human population, HCV showed a high degree of inter- and intra-
subtype genetic variability.
Protease inhibitors (PIs), a new class of drugs, have been designed speciﬁcally on the HCV genotype 1
NS3 protease three-dimensional structure. The viral genetic barrier limits the efﬁcacy of PIs, and fourteen
loci in the HCV NS3 gene are involved in resistance to PIs. A sensitive method (15 UI/ml) for study the
HCV genetic proﬁle of 125 strains from patients naïve to PIs, was developed through the use of new
degenerate primers for subtype 1b.
We observed the presence of naturally resistance-associated variants in 14% of the HCV strains (V36L,
F43S, T54S, I153V, R155Q, D168A/G). T54S was the most common mutation (4%) detected.
We investigated, through minimal score (m.s.) calculating, how the HCV intra-subtype 1b variability
modiﬁes the genetic barrier to PIs. For >60% of strains a single transition (m.s. of 1) was required for selec-
tion of low to medium resistance mutations, while more than one transition/transversion (m.s.P2.5) or
one transition plus one transversion (m.s. P3.5) was necessary for most of the high level PI-resistant-
associated mutations, except for A156V, for which a single transition was sufﬁcient (m.s. of 1). However,
the presence at locus 36 of the amino acid polymorphism S36 in one case and the wild type V36 in 6 iso-
lates, encoded by unusual GTA or GTG codons, might determined a higher probability of V36L/M muta-
tions because of the reduction of the genetic barrier. Instead, the presence of the CGA and CGT codons in
the 155th position increases the genetic barrier for R155M or R155Q/M.
The large intra-subtype variability, suggests that a routine baseline resistance test must be used before
PIs-treatment.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) is an enveloped positive single-stranded
RNA virus from the family Flaviviridae and the genus Hepacivirus.
HCV genome carriers a single, long open reading frame (ORF)
encoding a polyprotein that is cleaved co- and post-translationally
into 10 different polypeptides. The serine protease encoded by the
NS3 gene, has an essential role in the viral replication and is there-
fore the target for a new class of direct acting antivirals (DAA) com-
pounds named protease inhibitors (PIs) (Pawlotsky et al., 2007).
The high genetic diversity of HCV (genotypes, subtypes and
quasispecies) is linked to the high viral production rates
(1011–1012 virions/day), to error-prone RNA polymerase, and tothe lack of proof-reading mechanisms, which generate a high
mutation rate (>1/105 nucleotides/replication cycle). All possible
single and double nucleotide mutations are generated daily
(Powdrill et al., 2011).
The genetic variability affects the response to old and new ther-
apies. Indeed, the HCV genotype 1, the most widespread in the
world, is associated with a minor rate of sustained virological re-
sponse to standard of care therapy (pegIFN plus RBV) (Mchutchi-
son et al., 2009). Although, the PIs–drugs has been designed
speciﬁcally on HCV-1 NS3 protease three-dimensional structure,
the different HCV-1 subtypes showed a diverse probability of
development of resistance variants because of a diverse genetic
barrier to PIs, deﬁned as the number and the type (transition/
transversion) of nucleotide substitution required to select muta-
tions (Götte, 2012). Two linear peptidomimetics ketoamides, boce-
previr (BOC) and telaprevir (TVR), have been approved in triple
combination regimes with the standard of care for the treatment
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tors, including BI-201335 (faldaprevir), TMC-435 (simeprevir),
ITMN-191 (danoprevir), BMS-650032 (asunaprevir) and MK7009
(vaniprevir), are in various phases of clinical trials. Fourteen loci
in the HCV NS3 gene are currently involved in resistance to PIs
as demonstrated by replicon systems. The mutations are classiﬁed
as low (0–10 fold), medium (10–100 fold), and high (>100 fold)
according to the level of resistance caused in vitro, deﬁned as the
fold of change in the concentration of drug at which the HCV
RNA level is reduced by 50% (EC/IC50) compared with wild type
(Bartels et al., 2008). The mutations R155K/T/Q/M and A156M/S/
T/V reduce the susceptibility to the most PIs. V36A/M/L, Q41R,
F43S, T54A/S, V55A, R109K, I153V, and V170A/T are associated
with resistance to the linear PIs, while the mutations Q80R/K,
S122R, S138T, and D168A/V/T/H/N/G are selected only by macrocy-
clic PIs (Gaudieri et al., 2009; Lenz et al., 2010).
In the perspective of future IFN-free PIs therapy, we evaluated
in HCV subtype 1b strains, from patients with chronic infection na-
ive to PIs, the intra-subtype variability to identify the frequency of
resistance associated-variants (RAVs) and the presence of natural
nucleotide and amino acid polymorphisms able to modify the ge-
netic barrier to PIs.2. Materials and methods
2.1. Samples
We studied 125 strains from Sicilian patients with HCV subtype
1b infection and chronic liver disease assessed by liver biopsy ob-
served at the Liver Unit of the University of Palermo between
November, 2008 and February, 2010. All patients (M/F: 75/50,
mean age: 60 years) were HCV-RNA positive (mean level of serum
HCV RNA: 4  106 UI/ml) and naïve for antiviral therapies. None
were co-infected by HBV and/or HIV.2.2. Methods
Viral RNA was extracted from 140 ll of serum using the QIA-
amp Viral RNA Mini Kit (Qiagen, Hilden, Germany), according to
manufacturer’s instructions. A fragment of 495 bp encoding the
HCV NS3 protease catalytic domain was obtained with an in-house
RT nested PCR using new degenerate primers (NS3–3131F 50-GG
YTGYATCATYACYAGYCT-30 and NS3-3675R 50-AATGWCTGCGG
YACRGCSG-30, NS3-3154F 50-GGCCGGGAYAARAACCAGGT-30 and
NS3-3649R 50-GARTTRTCCGTRAARACCGGG-30) designed on some
Sicilian HCV-1b NS3 sequences obtained from patients with high
viral load (HCV RNA >100000 UI/ml) by Sarrazin et al., 2007 proto-
cols. The ﬁrst round of PCR was done with the SuperScript III One-
Step RT-PCR System with Platinum Taq DNA Polymerase
(Invitrogen, Carlsbad, CA, USA), according to manufacturer’s
instructions. RT-PCR cycling conditions consisted of an initial incu-
bation at 50 C for 60 min, a hot-start at 94 C for 2 min, 40 cycles,
each at 94 C for 45 s, at 52 C for 45 s, and at 68 C for 45 s, and a
ﬁnal step at 68 C for 5 min. 5 ll of ﬁrst-round PCR product were
added to 45 ll of reaction mixtures containing the AccuPrime Pfx
DNA polymerase system (Invitrogen, Carlsbad, USA). The nested
PCR thermal cycle was characterized by a hot-start at 94 C for
3 min, followed by 40 cycles, each at 94 C for 30 s, at 55 C
for 30 s, and at 68 C for 45 s, and by a ﬁnal extension at 68 C
for 7 min. Standard procedures for reducing contamination were
strictly followed. The sensitivity of the RT-PCR was tested using
serial dilutions of Italian reference HCV-1b positive serum (HCV
RNA ISS/1005, Pisani et al., 2007) containing 1000 IU/ml.
The nucleotide sequence of the sense and antisense strands
was determined by direct sequencing, using the ABI Prism BigDye Terminator v 1.1 Cycle Sequencing Kit and an automated se-
quencer ABI Prism 3100 instrument (Applied Biosystems). HCV se-
quences found in GenBank (GenBank accession Nos.: AF009606,
JN704295, AF369247, AF483269, AJ132996, AJ132997, AJ238799,
AJ238800, EU155381, EU255382, EU482833, EU781832,
JN120912, JN704289, JN704297, JN704299, U45476, AY651061,
HM568433, AM910652, AF369216, AY051292) were used to con-
ﬁrm the HCV 1b subtype. All sequences were aligned with the
Clustal W algorithm integrated into the BioEdit software, and the
phylogenetic tree was constructed with the Mega 4.1 program
using the Kimura two-parameter system and the Neighbor-joining
method (bootstrap 1000 replicates). One consensus sequence, was
constructed by Bioedit software using the 125 sequences obtained
and choosing 60% of threshold frequency. Primary resistance muta-
tions and/or natural polymorphisms were identiﬁed by visual
inspection. The HCV genetic barrier was evaluated using the min-
imal score calculation: a score of 1 was assigned to each transition
(A–G and C–T), and a score of 2.5 to each transversion (A–C, A–T,
G–C and C–T) (van de Vijver et al., 2006, Svicher et al., 2011).3. Results
Analysis of the amino acid sequences from 36 to 176 residues of
the NS3 protein of HCV subtype 1b isolates obtained from 125 pa-
tients was done by an in-house direct sequencing method charac-
terized by a sensibility of 15 UI/ml. The phylogenetic tree (Fig. 1)
contained the 125 NS3 sequences and 22 HCV subtype 1 sequences
found in GenBank, conﬁrmed the 1b subtype for all isolates as
determined by reverse dot-blot INNOLiPa (Siemens Healthcare
Diagnostic, NY, USA).
HCV strains with mutations able to confer resistance to linear
and macrocyclic PIs were identiﬁed in 18 of the 125 strains
(14%). In particular, 1.6% isolates displayed a V36L mutation, 3.2%
a F43S, 4% a T54S, 3.2% an I153V, 0.8% an R155Q, 0.8% a D168A,
and 0.8% a D168G. These RAVs were detected as single mutations,
except for one isolate in which two mutations were found (F43S
plus T54S).
Amino acid polymorphisms V36G, V36S, Q80L, I153L, A156P,
V170L, V170S, and E176Q were observed in 8 isolates, V55I in 2
isolates, and V170I in 62 isolates. Double and triple polymorphisms
were detected in 3 different HCV strains (V36D + E176Q,
Q80L + V170I and A156P + V170S + E176R).
The presence of these amino acid polymorphisms (Table 1) usu-
ally increased the genetic barrier to PIs, as evaluated by minimal
score (m.s.) calculation, with 3 exceptions (S36, P156 and I170),
which instead reduced it. The TCT codon encoding for serine in
position 36 showed a m.s. of 1 for the S36L mutation versus a
m.s. of 2.5 for GTT of the wild type valine. The P156 polymorphism
reduced the m.s. from 2.5 to 1, and from 3.5 to 2 for P156S
and P156G mutations, respectively. Polymorphism I170 showed
a m.s. of 1 versus 2 for the consensus sequence for the V170T
mutation.
Synonymous mutations in the nucleotide triplets for a wild-
type amino acid change the genetic barrier at various levels of
the m.s. In most HCV isolates the presence of polymorphic codons
did not affect the genetic barrier to PIs, except for the 36th and
155th positions of the NS3 domain of 13 strains. The wild-type ami-
no acid valine at position 36 was encoded by a GTA codon in 4 iso-
lates, and by a GTG codon in 2 strains, thus determining a
reduction of them.s. for the V36 M from 3.5, calculated for the con-
sensus sequence, to 2 for GTA, and to 1 for GTG. The CGA codon in
the 155th position observed in 6 cases increased the m.s., from 5 to
6, only for the R155 M mutation, and to 7.5 when the CGT codon
was present (1 strain). The CGT codon also increased the m.s., from
1 to 3.5, for the R155Q mutation (Table 2).
Fig. 1. Phylogenetic tree of 125 HCV-NS3 isolates and HCV-1 sequences referred in GenBank constructed using Kimura two-parameter system and Neighbor-joining method,
bootstrap 1000 replicates.
Table 1
Prevalence of amino acid polymorphisms in resistance-associated positions and their impact on genetic barrier to PIs in 125 isolates of HCV-1b.
No. of isolates (%) Mutation m.s. Mutation m.s. Mutation m.s. Mutation m.s. Mutations m.s. Mutation m.s. Mutation m.s.
V36 120 (96) V36A 1.0 V36M 3.5 V36L 2.5
S36 1 (0.8) 2.5 6.0 1.0
D36 1 (0.8) 2.5 6.0 5.0
G36 1 (0.8) 2.5 6.0 5.0
V55 123 (98.4) V55A 1.0
I55 2 (1.6) 2.0
Q80 123 (98.4) Q80R 1.0 Q80H/K 2.5
L80 2 (1.6) 2.5 5.0
I153 120 (96) I153V 1.0
L153 1 (0.8) 2.5
A156 123 (98.4) A156T 2.5 A156V 1.0 A156D 2.5 A156S 2.5 A156F 3.5 A156G 2.5 A156 N 3.5
P156 2 (1.6) 2.5 3.5 3.5 1.0 2.0 5.0 5.0
V170 60 (48) V170A 1.0 V170T 2.0
I170 63 (50.4) 2.0 1.0
L170 1 (0.8) 3.5 3.5
S170 1 (0.8) 2.5 2.5
E176 122 (97.6) E176G 1.0 E176K 1.0
Q176 2 (1.6) 2.5 2.5
R176 1 (0.8) 1.0 1.0
m.s.: minimal score, a score of 1 was assigned to each transition, and a score of 2.5 to each transversion.
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ity of selection of low, medium and high PI-resistant mutations, on
the basis of the in vitro fold resistance and the replication level
compared to HCV-1b wild type (Lenz et al., 2010; McPhee et al.,
2012; Mani, 2012). As shown in Tables 3, for the selection of the
low resistant mutations, such as T54A to boceprevir and telaprevir,V36A to telaprevir and asunaprevir, Q41R to simeprevir and vani-
previr, F43S to vaniprevir, Q80R to asunaprevir, danoprevir and
simeprevir, D168N to simeprevir, single transitions (m.s. of 1) were
necessary. The same conditions were identiﬁed for the medium
resistant mutations V170A to boceprevir, R155Q and D168G to
faldaprevir. The only high resistant mutation with a m.s. of 1 was
Table 2
Synonymous mutations able to modify the genetic barrier to PIs in 125 isolates of HCV-1b.
Codon No. of isolates Mutation m.s. Mutation m.s. Mutation m.s. Mutation m.s.
V36 GTC 42 V36M 3.5 V36L 2.5 V36A 1.0
GTT 72 3.5 2.5 1.0
GTA 4 2.0 2.5 1.0
GTG 2 1.0 2.5 1.0
R155 CGG 117 R155K 3.5 R155T 5.0 R155Q 1.0 R155M 5.0
CGA 6 3.5 5.0 1.0 6.0
CGT 1 3.5 5.0 3.5 7.5
m.s.: minimal score, a score of 1 was assigned to each transition, and a score of 2.5 to each transversion.
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to telaprevir, faldaprevir and simeprevir. One transversion or
one/two transversions plus one transition (m.s. of 2.5–5) were nec-
essary for the selection of the main low to high primary mutations,
such as the low-medium R155 G/M/T mutations, which showed
and m.s. of 5, and the high resistance mutations F43V, R155K,
A156Tand D168A/H/Y/T/V with a m.s. of 2.5–3.5.4. Discussion
The high genetic diversity of HCV, due to its high viral produc-
tion rate and to the error-prone RNA polymerase, allows the virus
to adapt rapidly to DAA drugs through the selection of RAVs, as
demonstrated in both replicon and clinical studies (Bartenschlager
and Lohmann, 2000; Lin et al., 2004). The ﬁrst generation of PIs
drugs was designed speciﬁcally on the HCV genotype 1 NS3 prote-
ase three-dimensional structure. Mutations at positions V36, T54,
R155 or A156 are the principal RAVs selected under PI therapy
(Kieffer et al., 2007; Sarrazin and Zeuzem, 2010). Reductions in
PIs efﬁcacy were found in patients infected by different subtypes
of genotype 1 or by non-genotype 1 (Cento et al., 2012).
Clinical studies of telaprevir alone or in combination with PEG
IFN, the viral breakthrough and selection of RAVs have been ob-
served more frequently in patients infected with HCV-1a then
HCV-1b (McHutchison et al., 2009; Kieffer et al., 2007) because a
single nucleotide change was required for the selection of V36M
and R155K resistance mutations in HCV-1a while two changes in
HCV-1b (Sarrazin and Zeuzem, 2010). In 2013 Cento et al. identi-
ﬁed the uncommon HCV subtype 1g, in a non-responder to boce-
previr-based therapy. HCV-1g NS3 sequences showed the
resistance substitution T54S, plus P131S and L135F changes, lo-
cated in the highly conserved NS3 positions within the bocepre-
vir-binding site.
Because of HCV-1b variability of NS3 gene, to obtain a very sen-
sitive protocol for HCV RNA detection (>15 UI/ml) and for assessing
the resistance proﬁle of 125 strains from PIs-naïve patients, we
used new degenerated primers speciﬁcally designed on Sicilian
HCV subtype 1b sequences. The phylogenetic analysis of these se-
quences conﬁrmed the subtype 1b, previously assessed by LiPA,
and ruled out uncommon HCV subtypes (1c–1m) (Nakano et al.,
2012; Cento et al., 2013).
Primary mutations associated with low and medium level of
resistance to PIs (V36L, F43S, T54S, I153V, R155Q, D168G) were
found in 14% of the HCV strains, as reported in other studies of
PIs-naïve patients (Vicenti et al., 2012; Paolucci et al., 2012; Bartels
et al., 2013). D168A, a high resistance mutation, was identiﬁed in
only one viral isolate (0.8%). T54S was the most common mutation
(4%) detected in our study. Recently, an Italian study (Vicenti et al.,
2012) found mutations V36L in 7% and T54S in 3.5% of 28 HCV sub-
type 1b isolates. The T54S mutation was associated in vitro with a
low level of resistance to BOC and TVR, increasing the EC50 by 8.5
and 4.2-fold, respectively (Lenz et al., 2010). T54S was found, at thetime of treatment failure with TVR, in approximately 7% of HCV
subtype 1b infected patients (Kieffer et al., 2012) and in a patient
infected by HCV subtype 1g and not responsive to triple therapy
with BOC (Cento et al., 2013). Two isolates with a T54S mutation
were also characterized by the simultaneous presence of the poly-
morphism V55I. The T54S and V55I double variants have shown, in
a replicon system, a clinically signiﬁcant 7.9-fold increase in the
TVR EC50. The V55I alone determined no signiﬁcant increase in
EC50 for BOC and only a 1.4-fold increase for TVR (Welsch et al.,
2012). Q80K, which is expected to confer resistance to simeprevir
and to a second generation PI-inhibitor ACH-1625 when found in
HCV subtype 1a (Palanisamy et al., 2013; Fabrycki et al., 2012),
was not detected in our population of 1b infected patients. V36M
and R155K, the most common RAVs identiﬁed in HCV-1a isolates,
were not found in our HCV-1b isolates according to the higher ge-
netic barrier to generation them (Sarrazin and Zeuzem, 2010). Var-
ious amino acid polymorphisms were detected in RAV-associated
positions, and the impact of the most of these unproven resistance
mutations on the PIs susceptibility and on the HCV ﬁtness has
never been studied directly. Only V36G and Q80L polymorphisms
have been partially characterized in vitro. The rare variant V36G
determined an 11.2-fold decrease in sensitivity to TVR (Zhou
et al., 2008), while the Q80L polymorphism was characterized by
a 2.1-fold decrease in simeprevir susceptibility (Lenz et al., 2010).
An important viral factor affecting the outcome of drug therapy
is the intrinsic viral genetic barrier to generating resistance muta-
tions, which may also affect the likelihood of having RAVs.
With an HIV and HBV model (van de Vijver et al., 2006; Svicher
et al., 2011), we analyzed the genetic barrier with the m.s. calcula-
tion, assigning different values for the type of nucleotide substitu-
tions, because transitions, rather than transversions, were more
likely to occur in HCV (Powdrill et al., 2011). HCV strains of differ-
ent genotype and subtype are prone differently to the development
of PI-resistant mutations (Cento et al., 2012), but little is known
about how the intra-subtype variability inﬂuences the genetic bar-
rier. Within subtype 1b, some viral isolates may have a lower ge-
netic barrier as isolates belonging to 1a subtype.
In this study, for >60% of strains a single transition (m.s. of 1)
was required for selection of low to medium resistance mutations,
while more than one transition/transversion (m.s.P2.5) or one
transition plus one transversion (m.s.P3.5) was necessary for most
of the high level PI-resistant-associated mutations, except for
A156V, for which a single transition was sufﬁcient (m.s. of 1).
Selection of this mutation, despite the very low genetic barrier ob-
served, has rarely been found at the time of treatment failure, due
to the reduction of replicative ﬁtness, 80% less than wild type, asso-
ciated with it (Lenz et al., 2010). In our preliminary study of HCV
strains from patients under triple therapy with TVR, A156V variant
was identiﬁed, after two weeks of treatment, in two patients with
sustained virological response.
Some HCV subtype 1b isolates show an altered genetic barrier
due to the presence of amino acid and/or nucleotide polymor-
phisms in resistance-related positions. Presence at locus 36 of
Table 3
Genetic barrier of >60% of HCV-1b isolates to low, medium and high resistance mutations.
Low resistance mutation (0–10-fold
resistance)
Medium resistance mutation (10–100 fold
resistance)
High resistance mutation (>100 fold resistance)
Drug Mutation FR m.s. RL (%) Mutation FR m.s. RL (%) Mutation FR m.s. RL (%)
Boceprevir V36M 2.9 3.5 43 A156S 24 2.5 71 A156T 128 2.5 30
F43S 3.5 2.5 63 V170A 19 1 30
R155K 3.6 3.5 40
T54A 6.7 1 61
Telaprevir V36L 2.2 2.5 56 V36G 11 2.5 ND A156T 105 2.5 30
T54S 4.2 2.5 ND R155T 20 5 7 A156V 112 1 18
R155M 5.6 5 33 A156F 65 3.5 ND
T54A 6.3 1 61
V36M 7 3.5 43
V36A 7.4 1 22
R155G 7.4 5 4
R155K 7.4 3.5 40
A156S 9.6 2.5 71
Faldaprevir V36M 2.1 3.5 43 R155Q 60 1 10 A156V 150 1 18
Q80K 2.2 2.5 98 D168G 80 1 ND A156T 270 2.5 30
T54S 3.5 2.5 ND R155K 350 3.5 40
D168A 690 2.5 90
D168V 970 2.5 94
Simeprevir Q41R 1.9 1 ND F43I 89 2.5 ND F43V 100 2.5 ND
Q80H 3.4 2.5 ND F43V 99 2.5 ND A156V 196 1 18
D168N 5.5 1 67 A156G 19 2.5 66 D168T 334 3.5 192
Q80R 6.4 1 40 A156T 37 2.5 30 D168H 401 2.5 104–12
Q80K 7.8 2.5 98 D168Y 651 2.5 30
D168A 784 2.5 90
D168V 3100 2.5 94
Vaniprevir Q41R 3.3 1 ND A156T 125 2.5 30
F43S 4.9 1 63 R155K 219 3.5 40
D168Y 269 2.5 30
Danoprevir Q80K 2.3 2.5 98 D168H 133 2.5 104
Q80R 3.5 1 40 D168A 153 2.5 90
D168T 300 3.5 192
D168Y 391 2.5 30
R155K 410 3.5 40
Asunaprevir V36A 2 1 22 D168H 100 2.5 104
V36M 2 3.5 43 D168A 127 2.5 90
F43S 4 2.5 63 D168Y 238 2.5 30
Q80R 4 1 40 D168V 280 2.5 94
A156T 6 2.5 30 D168H 100 2.5 104
Q80K 6.5 2.5 98 D168A 127 2.5 90
A156S 7 2.5 71 D168Y 238 2.5 30
FR: fold resistance referred to HCV-1b (Lenz, Antimicrobial Agents and Chemotherapy 2010, McPhee, Antimicrobial Agents and Chemotherapy 2012, Mani, Ann Forum Collab
HIV Res 2012). m.s.: minimal score, a score of 1 was assigned to each transition, and a score of 2.5 to each transversion. RL: replication level % of that for HCV-1b wild type
(Lenz, Antimicrobial Agents and Chemotherapy 2010).
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and the wild type V36 in 2 isolates, encoded by GTG codon as in
HCV-1a, and in 4 isolates by GTA codon. The presence of these unu-
sual codons might determined a higher probability of V36L/M
mutations because of the reduction in the m.s. from 3.5 to 1 for
GTG and to 2 for GTA. In these 6 isolates the presence, in 155 posi-
tion of the common CGG codon (m.s. 3.5), reduced the probability
of selection of double mutation (V36M + R155K) than HCV-1a. In-
stead, the presence in the 155th position of the CGA in 6 and
CGT codons in 1 isolates, increases the genetic barrier for R155 M
or R155Q/M.
The large NS3 genetic intra-subtype variability, associated with
the selection of RAVs, suggests, as just reported (Poveda and Sori-
ano, 2012), that a routine baseline resistance test must be used be-
fore PIs-treatment.
Due to the spread worldwide, and probable long-term presence
in human population (Simmonds, 2004), HCV subtype 1b strains
showed a high degree of genetic variability.
In Sicily, a southern Italian region of high prevalence for HCV,
after introduction during the Second World War (Ferraro et al.,
2008) the endemic subtype 1b infection (prevalence of 76.7%)
(Pizzillo et al., 2009) evolved determining the selection of RAVs(14% of cases) and strains with natural amino acid and nucleotide
polymorphisms able to inﬂuenced the genetic barrier to DAA.
A very sensitive direct sequencing method may be a useful tools
for the molecular characterization of HCV strains from patients
prior and under therapy, from the identiﬁcation of common and
uncommon subtype to the study of genetic barrier and the kinetic
evolution of RAVs. This could be important for the best use of com-
bination regimens of HCV PI-inhibitors in future IFN-free regimens.References
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